🇺🇸 FDA
Patent

US 10905709

Modified antisense oligomers for exon inclusion in spinal muscular atrophy

granted A61KA61K31/712A61K31/7125

Quick answer

US patent 10905709 (Modified antisense oligomers for exon inclusion in spinal muscular atrophy) held by Sarepta Therapeutics, Inc. expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sarepta Therapeutics, Inc.
Grant date
Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K31/712, A61K31/7125, A61P, A61P21/00